Cargando…

BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694

BACKGROUND: Stereotactic radiosurgery (SRS) is an increasingly common modality used with or without surgery for brain metastases (BM). However, biological effect of SRS to tumors in vivois not known. METHODS: Patients were treated with SRS prior to surgery as per the clinical trial protocol. The res...

Descripción completa

Detalles Bibliográficos
Autores principales: Huff, Wei, Shireman, Jack, Monaco, Gina, Agrawal, Namita, Park, Cheol, Saathoff, Miranda, Henriquez, Mario, Watson, Gordon, Ahmed, Atique, Dey, Mahua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213312/
http://dx.doi.org/10.1093/noajnl/vdz014.017
_version_ 1783531777328939008
author Huff, Wei
Shireman, Jack
Monaco, Gina
Agrawal, Namita
Park, Cheol
Saathoff, Miranda
Henriquez, Mario
Watson, Gordon
Ahmed, Atique
Dey, Mahua
author_facet Huff, Wei
Shireman, Jack
Monaco, Gina
Agrawal, Namita
Park, Cheol
Saathoff, Miranda
Henriquez, Mario
Watson, Gordon
Ahmed, Atique
Dey, Mahua
author_sort Huff, Wei
collection PubMed
description BACKGROUND: Stereotactic radiosurgery (SRS) is an increasingly common modality used with or without surgery for brain metastases (BM). However, biological effect of SRS to tumors in vivois not known. METHODS: Patients were treated with SRS prior to surgery as per the clinical trial protocol. The resected tumor was divided into two groups: ‘center’ and ‘periphery’ with respect to the center of SRS treatment with periphery within 50%-isodose-line. Tissue was analyzed by whole exome sequencing (WES) and compared between the two groups as well as to non-radiated control tissues. RESULTS: All sequenced samples contained greater than 95% clean reads with an average read density of 100 base pairs and mapping efficiency of >99%. Preliminary analysis focused on SNP and Indel detection. In pooled groups with n=7 replicates there was no statistically significant differences in total mutation burden in either SNP’s or Indels compared between controls and both treatment locations. Delving deeper intronic, frameshift, missense, and nonsense mutations all also showed insignificant changes between controls and center or peripheral tumor locations (p >0.5, p >0.1, p >0.4, p >0.3 respectively) hinting that at a pooled biological level there are not significant mutational burdens between treatment locations. However, at the individual level, matched comparison of SRS samples originating from the center or periphery of the same tumor showed total mutational burden differences. 6 out of 7 (86%) patients showed decreased total number of indels in peripheral vs. center and 5 out of 7 (71%) patients showed decreased number of SNP’s in peripheral vs. center locations. CONCLUSION: Ultimately, these data demonstrate the power of matched patient controls over bulk analysis in order to elucidate smaller but possibly biologically meaningful effects, and point to a possible location dependency in treatment associated mutation burden within a single patient and single tumor that may be masked at a population level.
format Online
Article
Text
id pubmed-7213312
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72133122020-07-07 BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 Huff, Wei Shireman, Jack Monaco, Gina Agrawal, Namita Park, Cheol Saathoff, Miranda Henriquez, Mario Watson, Gordon Ahmed, Atique Dey, Mahua Neurooncol Adv Abstracts BACKGROUND: Stereotactic radiosurgery (SRS) is an increasingly common modality used with or without surgery for brain metastases (BM). However, biological effect of SRS to tumors in vivois not known. METHODS: Patients were treated with SRS prior to surgery as per the clinical trial protocol. The resected tumor was divided into two groups: ‘center’ and ‘periphery’ with respect to the center of SRS treatment with periphery within 50%-isodose-line. Tissue was analyzed by whole exome sequencing (WES) and compared between the two groups as well as to non-radiated control tissues. RESULTS: All sequenced samples contained greater than 95% clean reads with an average read density of 100 base pairs and mapping efficiency of >99%. Preliminary analysis focused on SNP and Indel detection. In pooled groups with n=7 replicates there was no statistically significant differences in total mutation burden in either SNP’s or Indels compared between controls and both treatment locations. Delving deeper intronic, frameshift, missense, and nonsense mutations all also showed insignificant changes between controls and center or peripheral tumor locations (p >0.5, p >0.1, p >0.4, p >0.3 respectively) hinting that at a pooled biological level there are not significant mutational burdens between treatment locations. However, at the individual level, matched comparison of SRS samples originating from the center or periphery of the same tumor showed total mutational burden differences. 6 out of 7 (86%) patients showed decreased total number of indels in peripheral vs. center and 5 out of 7 (71%) patients showed decreased number of SNP’s in peripheral vs. center locations. CONCLUSION: Ultimately, these data demonstrate the power of matched patient controls over bulk analysis in order to elucidate smaller but possibly biologically meaningful effects, and point to a possible location dependency in treatment associated mutation burden within a single patient and single tumor that may be masked at a population level. Oxford University Press 2019-08-12 /pmc/articles/PMC7213312/ http://dx.doi.org/10.1093/noajnl/vdz014.017 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Huff, Wei
Shireman, Jack
Monaco, Gina
Agrawal, Namita
Park, Cheol
Saathoff, Miranda
Henriquez, Mario
Watson, Gordon
Ahmed, Atique
Dey, Mahua
BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
title BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
title_full BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
title_fullStr BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
title_full_unstemmed BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
title_short BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
title_sort bsci-19. effect of stereotactic radiosurgery on non-small cell lung cancer brain metastasis: correlative radiobiologic analysis from phase-ii clinical trial nct03398694
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213312/
http://dx.doi.org/10.1093/noajnl/vdz014.017
work_keys_str_mv AT huffwei bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT shiremanjack bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT monacogina bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT agrawalnamita bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT parkcheol bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT saathoffmiranda bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT henriquezmario bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT watsongordon bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT ahmedatique bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694
AT deymahua bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694